China-Anti-Allergy-Drug-Report - 2008

Published by: Draco Healthcare Consulting LLC

Published: Apr. 1, 2009 - 63 Pages

Table of Contents

Top 20 Pharmaceutical Companies in China’s Anti-Allergic Drug Market (at least with >0.84% of the total market shares)

Chapter I: Overview of Allergy Drugs

Section 1: Overview of Allergy Drugs

Allergic Rhinitis (AR)

Allergic Asthma (AA)

Allergic Purpura (AP)

Anti-allergy Drugs

1. The 1st generation antihistamine drugs

2. The 2nd generation antihistamine drugs

3. The 3rd generation antihistamine drugs

Section 2: R&D of Allergy drugs

Chapter II: The Chinese Market of Allergy Drugs

Section 1: Market size of Allergy Drugs

Section 2: Market Shares of Top Allergy Drugs

Section 3: Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Allergy Drug Market

Section 4: Growth Analysis of Top Allergy Drugs

Section 5: New Drug Approvals and Patent Applications of Allergy Drugs

5.1 Newly Approved Allergy Drugs in 2007 in China

5.2 Patent Applications for Allergy Drugs in China

Chapter III: Key Allergy Drugs in the Chinese Market

Section 1: Market Shares, Market Sizes and Manufacturers of Loratadine

Section 2: Market Shares, Market Sizes and Manufacturers of Cetirizine

Section 3: Market Shares, Market Sizes and Manufacturers of Desloratadine

Section 4: Market Shares, Market Sizes and Manufacturers of Mizolastine

Section 5: Market Shares, Market Sizes and Manufacturers Levocetirizine

Section 6: Market Shares, Market Sizes and Manufacturers of Ebastine

Section 7: Market Shares, Market Sizes and Manufacturers of Epinastine

Section 8: Market Shares, Market Sizes and Manufacturers of Fexofenadine

Section 9: Global Sales of Allergy Drugs

Chapter IV: Pricing Control on Allergy Drugs & Allergy Drugs on the National

Basic Healthcare Insurance List

Section 1: Price Control on Certain Drugs

Section 2: Allergy Drugs on the National Basic Healthcare Insurance List-04

Chapter V: Brand Names, Chemical Names and Manufacturers of Allergy Drugs in China

Exhibits

Table 1: Market Shares of Top Allergy Drugs in China 2005-2007

Table 2: Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Allergy Market 2006-2007

Table 3: Growth Rates of the Top 15 Allergy Drugs 2006-2007

Table 4: New Approvals of Major Allergy Drugs in 2007

Table 5: New Patents on Allergy Drugs in 2007

Table 6: Manufacturers, Formula, Brands and Market Shares of Loratadine 2006-2007

Table 7: Sales of Loratadine by Manufacturers 2006-2007

Table 8: Manufacturers, Formula, Brands and Market Shares of Cetirizine 2006-2007

Table 9: Sales of Cetirizine by Manufacturers 2006-2007

Table 10: Manufacturers, Formula, Brands and Market Shares of Desloratadine 2006-2007

Table 11: Sales of Desloratadine by Manufacturers 2006-2007

Table 12: Manufacturers, Formula, Brands and Market Shares of Mizolastine 2006-2007

Table 13: Sales of Mizolastine by Manufacturers 2006-2007

Table 14: Manufacturers, Formula, Brands and Market Shares of Levocetirizine 2006-2007

Table 15: Sales of Levocetirizine by Manufacturers 2006-2007

Table 16: Manufacturers, Formula, Brands and Market Shares of Ebastine 2006-2007

Table 17: Sales of Ebastine by Manufacturers 2006-2007

Table 18: Manufacturers, Formula, Brands and Market Shares of Epinastine 2006-2007

Table 19: Sales of Epinastine by Manufacturers 2006-2007

Table 20: Manufacturers, Formula, Brands and Market Shares of Fexofenadine 2006-2007

Table 21: Sales of Fexofenadine by Manufacturers 2006-2007

Table 22: Sales of Allergy Drugs in the World 2007

Table 23: Ranking of the Prescription Drugs by Prescription Volumes

Table 24: New Maximum Retail Prices of Patented and Innovative Allergy Drugs 2007

Table 25: New Maximum Retail Prices of GMP Allergy Drugs 2007

Table 26: Allergy Drugs on the National Basic Healthcare Insurance Lists 2004

Table 27: Brand Names, Chemical Names and Manufacturers of Allergy Drugs in China

Figure 1: Sales Trends of Allergy Drugs 2005-2007

Top 20 Pharmaceutical Companies in China’s Anti-Allergic Drug Market (at least with >0.84% of the total market shares)

Chongqing Huabang

India Ranbaxy Labs

Shenzhen Xinlitai

Zhejiang Hangzhou Aoyi Baoling

Beijing Shuanglu

Chengdu Minyi

Chongqing Kailin

Guangdong Zhuhai Lianbang

Hainan Puli

Henan Sanmenxia Sainuowei

Hubei Yidu Dongyang

Jiangsu Changzhou No 4 Pharma

Jiangsu Lianhuan

Nanjing Yihua

Schering-Plough China

Shandong Lunan

Shenzhen Haibin

Eisai

UCB

Xian-Janssen

Abstract

Statistic data indicate that the Chinese incidence of allergy diseases is as high as 37.3%. The incidences of allergy in the eastern coastal regions are higher than that in the inner land. The incidences of allergy in industrialized regions are higher than that in the rural areas. Under the government pricing control policies, the market growth of the allergy drugs has slowed down significantly in 2007. The sales of allergy drugs is about RMB 3.9 billion (USD 557 million) with only 2.63% same period growth in 2007

The allergy drug market has intense competitions. The market shares from the top 20 companies account for about 88.44% of the Chinese hospital allergy drug market in 2007, which is similar to the situation in 2006. The No.1 Company is still Schering-Plough, taking XX% of the total Chinese allergy drug market. Ioratadine and desloratadine are the two key allergy products from Schering-Plough. However, many generic products have recently been introduced in the market and have intensified the market competition. The market shares of Schering-Plough have been diluted greatly and have declined from 2006. Xian-Janssen is the No.2 player with XX% of the market. Xian-Janssen’s strong position in the allergy drug market is supported by the strong growth of its core allergy drug mizolastine. UCB is the 3rd player in 2007 with XX% of the market, fueled by its new product levocetirizine.

This report has systemically analyzed the Chinese allergy drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major allergy products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major allergy drugs will present you a clear picture of the competition landscape of Chinese allergy drug market and the market potential for your company’s product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Allergy Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.